Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autogene Cevumeran Alone and With Atezolizumab in Advanced Solid Tumors
NCT03289962Phase 1Completed
- Sponsor
- Genentech
- Start
- Dec 2017
- Primary completion
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 8
01
Overview
Phase 1, open-label trial of autogene cevumeran in melanoma, non-small cell lung cancer (NSCLC), bladder cancer and 5 more (5 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities at 21 days, Maximum Tolerated Dose/Recommended Phase 2 Dose of Autogene Cevumeran at 21 days and 7 more. Started Dec 2017; status: completed.
02
Drugs
autogene cevumeran
03
Conditions
melanomanon-small cell lung cancer (NSCLC)bladder cancercolorectal cancer (CRC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03289962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289962.